Por Renan Filho · 2026-10-11**Lead**
A novel injectable treatment designed to shrink the dangerous fat that wraps around internal organs has reduced visceral adipose tissue by an average of 12% in an early-stage human trial, researchers announced this week. The findings, presented at a major medical conference, mark a potential breakthrough in the fight against obesity-related metabolic disorders, offering a minimally invasive option for patients who struggle with stubborn belly fat that is linked to heart disease, diabetes, and liver problems.
The study, which involved a small group of volunteers with excess abdominal fat, tested a single injection of a proprietary compound that targets the molecular pathways responsible for storing visceral fat. Unlike subcutaneous fat—the pinchable layer under the skin—visceral fat lies deep within the abdomen, surrounding the liver, pancreas, and intestines. Its presence is strongly associated with insulin resistance, chronic inflammation, and a higher risk of cardiovascular events. The 12% reduction observed in the trial, while modest, is considered clinically meaningful because even small decreases in visceral fat can improve metabolic markers.
**Context**
Visceral fat has long been a focus of medical research because of its outsized role in metabolic disease. Unlike fat stored elsewhere, visceral fat releases inflammatory cytokines and free fatty acids that interfere with insulin signaling and promote systemic inflammation. Current treatment options include lifestyle changes—diet and exercise—which can be difficult to sustain, and bariatric surgery, which is invasive and carries significant risks. Pharmaceutical approaches, such as GLP-1 receptor agonists like semaglutide, have shown success in reducing overall body weight, but their effect on visceral fat specifically is variable and often requires chronic dosing.
The new injection, developed by a biotechnology company specializing in metabolic diseases, is designed to be administered directly into the abdominal region. The compound works by inhibiting a key enzyme involved in the formation and maintenance of visceral fat cells, triggering a localized breakdown of fat without affecting subcutaneous fat or muscle tissue. Preclinical studies in animal models had shown reductions of up to 30% in visceral fat, with no serious side effects. The early human trial, which enrolled 24 participants, was primarily designed to assess safety and tolerability, but the fat reduction data exceeded expectations.
Participants received a single injection and were monitored for 12 weeks. Researchers measured visceral fat volume using MRI scans before and after treatment. The average reduction of 12% was consistent across most participants, with some individuals experiencing reductions of up to 18%. No severe adverse events were reported; common side effects included mild injection-site discomfort and temporary swelling. The company plans to move into a larger Phase 2 trial later this year, testing multiple doses and longer follow-up periods.
**Analysis**
The potential impact of a targeted visceral fat injection extends beyond aesthetics. In the United States, more than 40% of adults are classified as obese, and a significant proportion have elevated visceral fat even at normal body weight—a condition sometimes called “normal-weight obesity.” These individuals face a higher risk of metabolic syndrome, non-alcoholic fatty liver disease, and type 2 diabetes, yet they often have few treatment options. A simple injection that specifically reduces visceral fat could fill a critical gap in the therapeutic arsenal.
However, experts caution that the results are preliminary. The small sample size and short duration mean that durability and long-term safety remain unknown. It is also unclear whether the fat reduction translates into improved clinical outcomes, such as lower blood sugar or reduced cardiovascular risk. The 12% reduction, while promising, may need to be larger or sustained over time to produce meaningful health benefits. Additionally, the injection does not address the root causes of visceral fat accumulation, such as poor diet, sedentary lifestyle, or genetic predisposition. It is best viewed as an adjunct to lifestyle interventions, not a replacement.
From a regulatory perspective, the U.S. Food and Drug Administration has not yet classified the compound, but if Phase 2 and Phase 3 trials confirm efficacy and safety, it could become the first approved injectable therapy specifically indicated for visceral fat reduction. The market potential is enormous: millions of Americans who are not candidates for surgery or who cannot tolerate systemic weight-loss drugs could be candidates. The company has not disclosed pricing, but analysts expect it to be comparable to other injectable metabolic therapies.
**Sources**
The information in this article is based on a press release issued by the biotechnology company developing the injection, as well as preliminary data presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in October 2026. Additional context was drawn from published research on visceral fat and metabolic disease in peer-reviewed journals such as *The New England Journal of Medicine* and *Cell Metabolism*. No independent verification of the trial data has been conducted by FORTIS NEWS.